GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (NAS:AVXL) » Definitions » PE Ratio
中文

Anavex Life Sciences (Anavex Life Sciences) PE Ratio

: At Loss (As of Today)
View and export this data going back to 2006. Start your Free Trial

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-04-24), Anavex Life Sciences's share price is $3.68. Anavex Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.55. Therefore, Anavex Life Sciences's PE Ratio for today is At Loss.


The historical rank and industry rank for Anavex Life Sciences's PE Ratio or its related term are showing as below:

AVXL' s PE Ratio Range Over the Past 10 Years
Min: At Loss   Med: At Loss   Max: At Loss
Current: At Loss



AVXL's PE Ratio is ranked worse than
100% of 250 companies
in the Biotechnology industry
Industry Median: 26.575 vs AVXL: At Loss

Anavex Life Sciences's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.11. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.55.

As of today (2024-04-24), Anavex Life Sciences's share price is $3.68. Anavex Life Sciences's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.55. Therefore, Anavex Life Sciences's PE Ratio without NRI for today is At Loss.

Anavex Life Sciences's EPS without NRI for the three months ended in Dec. 2023 was $-0.11. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.55.

During the past 3 years, the average EPS without NRI Growth Rate was -9.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was -8.00% per year. During the past 10 years, the average EPS without NRI Growth Rate was -4.50% per year.

During the past 13 years, Anavex Life Sciences's highest 3-Year average EPS without NRI Growth Rate was 35.30% per year. The lowest was -257.60% per year. And the median was -5.25% per year.

Anavex Life Sciences's EPS (Basic) for the three months ended in Dec. 2023 was $-0.11. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.55.


Anavex Life Sciences PE Ratio Historical Data

The historical data trend for Anavex Life Sciences's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anavex Life Sciences Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Anavex Life Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison

For the Biotechnology subindustry, Anavex Life Sciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anavex Life Sciences PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's PE Ratio distribution charts can be found below:

* The bar in red indicates where Anavex Life Sciences's PE Ratio falls into.



Anavex Life Sciences PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Anavex Life Sciences's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=3.68/-0.550
=At Loss

Anavex Life Sciences's Share Price of today is $3.68.
Anavex Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.55.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio or PE Ratio (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Anavex Life Sciences  (NAS:AVXL) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Anavex Life Sciences PE Ratio Related Terms

Thank you for viewing the detailed overview of Anavex Life Sciences's PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Anavex Life Sciences (Anavex Life Sciences) Business Description

Traded in Other Exchanges
Address
630 5th Avenue, 20th Floor, New York, NY, USA, 10111
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
Executives
Christopher U Missling director, officer: President, CEO, CFO, Treasurer, other: Secretary 61 MOULTON ST, CAMBRIDGE MA 02138
Athanasios Skarpelos 10 percent owner 14,RUE KLEBERG, GENEVA V8 CH-1201
Jiong Ma director 445 PARK AVENUE, 9TH FLOOR, NEW YORK NY 10022
Elliot Favus director 51 W 52ND STREET, 7TH FLOOR, NEW YORK NY 10091
Donhauser Peter D.o. director REGINA-KIRCHMAIER STRASSE 4, KAUFBEUREN 2M 87600
Sandra Boenisch officer: PFO & Treasurer 51 WEST 52ND STREET, 7TH FLOOR, NEW YORK NY 10019
Claus Vander Velden director PO BOX MUENSTEREIFELER ST., COLOGNE 2M 50937
Steffen Thomas director FALLMERAYER STR. 19, MUNICH 2M 80796
Bernd Metzner director 51 W 52ND STREET, 7TH FLOOR, NEW YORK NY 10019
George F Tidmarsh director, officer: Executive Director
John Robert Chisholm director 16308 36A AVENUE, SURREY A1 V3S 0X5
William Sean Lowry director 1172 BAY STREET, SUITE 300, ONTARIO Z4 M5S1L9
David L. Tousley director 14610 PAWNEE LANE, LEAWOOD KS 66224
Harvey Lalach director, officer: President CEO CFO 4837 CANYON RIDGE CRESENT, KELOWNA A1 V1W 4A1
Alison E. Ayers director 27 O'CONNOR CIRCLE, WEST ORANGE NJ 07052